Emmanuel Jouglar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emmanuel Jouglar has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Line Claude
Department of Radiation Oncology Centre Léon Bérard Lyon France
3 shared publications Alexandre Escande
Universitary Department of Radiation Oncology Centre Oscar Lambret Lille France
2 shared publications- Anne Laprie
Department of Radiation Oncology, University Institute of Cancer Toulouse-Oncopôle , Toulouse
2 shared publications Line Claude
Centre Léon-Berard, département de radiothérapie, 69008 Lyon, France
2 shared publications- Stéphane Supiot
Institut de Cancérologie de l’Ouest 12 , Saint-Herblain, France
2 shared publications A. de la Rochefordière
Department of Radiation Oncology, institut Curie, 26, rue de l'Ulm, 75005 Paris, France
1 shared publication
Latest Publications
- Open Access
- 12 April 2026
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 7
Towards establishing hippocampal dose constraints for pediatric brain tumor radiotherapy: protocol of the prospective multicentre IPANEMA study (Irradiation in pediatrics: Neurocognition, neuroimaging and evaluation of memory and attention)
- 12 April 2026
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 7
Open AccessTowards establishing hippocampal dose constraints for pediatric brain tumor radiotherapy: protocol of the prospective multicentre IPANEMA study (Irradiation in pediatrics: Neurocognition, neuroimaging and evaluation of memory and attention)
- Open Access
- 3 December 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 57, 101087
Reply to comment on impact of deep learning on CT-based organ-at-risk delineation for flank irradiation in paediatric renal tumours: A SIOP-RTSG radiotherapy committee
- 3 December 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 57, 101087
Open AccessReply to comment on impact of deep learning on CT-based organ-at-risk delineation for flank irradiation in paediatric renal tumours: A SIOP-RTSG radiotherapy committee
- Open Access
- 19 February 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100932
From pre-clinical studies to human treatment with proton-minibeam radiation therapy: adapted Idea, Development, Exploration, Assessment and Long-term evaluation (IDEAL) framework for innovation in radiotherapy
- 19 February 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100932
Open AccessFrom pre-clinical studies to human treatment with proton-minibeam radiation therapy: adapted Idea, Development, Exploration, Assessment and Long-term evaluation (IDEAL) framework for innovation in radiotherapy
- 26 October 2023
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 27 (8) , 736-745
Caractéristiques de la radiothérapie chez les adolescents et les jeunes adultes
- 26 October 2023
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 27 (8) , 736-745
Caractéristiques de la radiothérapie chez les adolescents et les jeunes adultes
- Open Access
- 4 September 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (12) , e29950
Locoregional failure after postoperative flank irradiation for nephroblastoma: Results from the French cohort of the SIOP‐2001 trial
Objective: To describe locoregional failure (LRF) after postoperative flank radiotherapy (RT) among French patients with nephroblastoma included in the Société Internationale d'Oncologie Pédiatrique (SIOP)‐2001 protocol.Patients and methods: In selected SIOP‐2001 patients, planning with simulation computed tomography (CT) scan and posttreatment CT scan demonstrating LRF were registered and analyzed. LRF was contoured and classified as in‐field, marginal or out‐of‐field according to dose distribution.Results: Total 316 French SIOP‐2001 patients were treated with postoperative RT. Three patients with nephroblastoma developed LRF after flank RT. All failures were located within the retroperitoneum. In two patients, the relapse was within the RT field and in one it was classified as marginal.Conclusion: LRF after postoperative flank RT for nephroblastoma was rare and exclusively situated in the retroperitoneum. These results point out this region as the most at risk of local relapse. A prospective evaluation of a target volume restricted to the retroperitoneum allowing the use of modern and highly conformal radiation techniques in order to decrease dose to normal tissues shall be encouraged.
- 4 September 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (12) , e29950
Open AccessLocoregional failure after postoperative flank irradiation for nephroblastoma: Results from the French cohort of the SIOP‐2001 trial
Objective: To describe locoregional failure (LRF) after postoperative flank radiotherapy (RT) among French patients with nephroblastoma included in the Société Internationale d'Oncologie Pédiatrique (SIOP)‐2001 protocol.Patients and methods: In selected SIOP‐2001 patients, planning with simulation computed tomography (CT) scan and posttreatment CT scan demonstrating LRF were registered and analyzed. LRF was contoured and classified as in‐field, marginal or out‐of‐field according to dose distribution.Results: Total 316 French SIOP‐2001 patients were treated with postoperative RT. Three patients with nephroblastoma developed LRF after flank RT. All failures were located within the retroperitoneum. In two patients, the relapse was within the RT field and in one it was classified as marginal.Conclusion: LRF after postoperative flank RT for nephroblastoma was rare and exclusively situated in the retroperitoneum. These results point out this region as the most at risk of local relapse. A prospective evaluation of a target volume restricted to the retroperitoneum allowing the use of modern and highly conformal radiation techniques in order to decrease dose to normal tissues shall be encouraged.
- 8 July 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1125) , 20210176
Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: preliminary toxicity results of a national prospective multicenter study
Objectives: While hypofractionated stereotactic body radiotherapy (SBRT) has been largely adopted in the adult setting, its use remains limited in pediatric patients. This is due, among other factors, to fear of potential toxicities of hypofractionated regimens at a young age. In this context, we report the preliminary acute (<3 months from SBRT) and middle-term (3–24 months) toxicity results of a national prospective study investigating SBRT in pediatric patients. Methods: Between 2013 and 2019, 61 patients were included. The first 40 patients (median age: 12 y, range: 3–20) who completed a 2-year-follow-up were included in the present analysis. SBRT was used for treating lung, brain or (para)spinal lesions, either as first irradiation (35%) or in the reirradiation setting (65%). Results: Acute and middle-term grade ≥2 toxicities occurred in 12.5 and 7.5% of the patients, respectively. No grade ≥4 toxicities occurred. Almost all toxicities occurred in the reirradiation setting. Conclusion: SBRT showed a favorable safety profile in young patients treated for lung, brain, and (para)spinal lesions. Advances in knowledge: SBRT appeared to be safe in pediatric patients treated for multiple oncology indications. These results support further evaluation of SBRT, which may have a role to play in this patient population in the future.
- 8 July 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1125) , 20210176
Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: preliminary toxicity results of a national prospective multicenter study
Objectives: While hypofractionated stereotactic body radiotherapy (SBRT) has been largely adopted in the adult setting, its use remains limited in pediatric patients. This is due, among other factors, to fear of potential toxicities of hypofractionated regimens at a young age. In this context, we report the preliminary acute (<3 months from SBRT) and middle-term (3–24 months) toxicity results of a national prospective study investigating SBRT in pediatric patients. Methods: Between 2013 and 2019, 61 patients were included. The first 40 patients (median age: 12 y, range: 3–20) who completed a 2-year-follow-up were included in the present analysis. SBRT was used for treating lung, brain or (para)spinal lesions, either as first irradiation (35%) or in the reirradiation setting (65%). Results: Acute and middle-term grade ≥2 toxicities occurred in 12.5 and 7.5% of the patients, respectively. No grade ≥4 toxicities occurred. Almost all toxicities occurred in the reirradiation setting. Conclusion: SBRT showed a favorable safety profile in young patients treated for lung, brain, and (para)spinal lesions. Advances in knowledge: SBRT appeared to be safe in pediatric patients treated for multiple oncology indications. These results support further evaluation of SBRT, which may have a role to play in this patient population in the future.
- Open Access
- 1 November 2020
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 2 (1) , 20190046
Radiomics for radiation oncologists: are we ready to go?
Radiomics have emerged as an exciting field of research over the past few years, with very wide potential applications in personalised and precision medicine of the future. Radiomics-based approaches are still however limited in daily clinical practice in oncology. This review focus on how radiomics could be incorporated into the radiation therapy pipeline, and globally help the radiation oncologist, from the tumour diagnosis to follow-up after treatment. Radiomics could impact on all steps of the treatment pipeline, once the limitations in terms of robustness and reproducibility are overcome. Major ongoing efforts should be made to collect and share data in the most standardised manner possible.
- 1 November 2020
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 2 (1) , 20190046
Open AccessRadiomics for radiation oncologists: are we ready to go?
Radiomics have emerged as an exciting field of research over the past few years, with very wide potential applications in personalised and precision medicine of the future. Radiomics-based approaches are still however limited in daily clinical practice in oncology. This review focus on how radiomics could be incorporated into the radiation therapy pipeline, and globally help the radiation oncologist, from the tumour diagnosis to follow-up after treatment. Radiomics could impact on all steps of the treatment pipeline, once the limitations in terms of robustness and reproducibility are overcome. Major ongoing efforts should be made to collect and share data in the most standardised manner possible.
- 10 October 2020
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (2) , 203-209
Impact de l’âge et radiothérapie : points clés chez les AJA
- 10 October 2020
- Published by Elsevier in Bulletin du Cancer
- Vol. 108 (2) , 203-209
Impact de l’âge et radiothérapie : points clés chez les AJA
- 1 October 2020
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 24 (6-7) , 594-601
Faut-il moduler les contraintes de dose dans les organes à risque lors d’une irradiation en association avec un traitement anticancéreux systémique ?
- 1 October 2020
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 24 (6-7) , 594-601
Faut-il moduler les contraintes de dose dans les organes à risque lors d’une irradiation en association avec un traitement anticancéreux systémique ?
- Open Access
Influence of Radiotherapy Fractionation Schedule on the Tumor Vascular Microenvironment in Prostate and Lung Cancer Models
Background. The tumor vasculature acts as an interface for the primary tumor. It regulates oxygenation, nutrient delivery, and treatment efficacy including radiotherapy. The response of the tumor vasculature to different radiation doses has been disparately reported. Whereas high single doses can induce endothelial cell death, improved vascular functionality has also been described in a various dose range, and few attempts have been made to reconcile these findings. Therefore, we aimed at comparing the effects of different radiation fractionation regimens on the tumor vascular microenvironment. Methods: Lewis lung and prostate PC3 carcinoma-derived tumors were irradiated with regimens of 10 × 2 Gy, 6 × 4 Gy, 3 × 8 Gy or 2 × 12 Gy fractions. The tumor vasculature phenotype and function was evaluated by immunohistochemistry for endothelial cells (CD31), pericytes (desmin, α-SMA), hypoxia (pimonidazole) and perfusion (Hoechst 33342). Results: Radiotherapy increased vascular coverage similarly in all fractionation regimens in both models. Vessel density appeared unaffected. In PC3 tumors, hypoxia was decreased and perfusion was enhanced in proportion with the dose per fraction. In LLC tumors, no functional changes were observed at t = 15 days, but increased perfusion was noticed earlier (t = 9–11 days). Conclusion: The vascular microenvironment response of prostate and lung cancers to radiotherapy consists of both tumor/dose-independent vascular maturation and tumor-dependent functional parameters.
Open AccessInfluence of Radiotherapy Fractionation Schedule on the Tumor Vascular Microenvironment in Prostate and Lung Cancer Models
Background. The tumor vasculature acts as an interface for the primary tumor. It regulates oxygenation, nutrient delivery, and treatment efficacy including radiotherapy. The response of the tumor vasculature to different radiation doses has been disparately reported. Whereas high single doses can induce endothelial cell death, improved vascular functionality has also been described in a various dose range, and few attempts have been made to reconcile these findings. Therefore, we aimed at comparing the effects of different radiation fractionation regimens on the tumor vascular microenvironment. Methods: Lewis lung and prostate PC3 carcinoma-derived tumors were irradiated with regimens of 10 × 2 Gy, 6 × 4 Gy, 3 × 8 Gy or 2 × 12 Gy fractions. The tumor vasculature phenotype and function was evaluated by immunohistochemistry for endothelial cells (CD31), pericytes (desmin, α-SMA), hypoxia (pimonidazole) and perfusion (Hoechst 33342). Results: Radiotherapy increased vascular coverage similarly in all fractionation regimens in both models. Vessel density appeared unaffected. In PC3 tumors, hypoxia was decreased and perfusion was enhanced in proportion with the dose per fraction. In LLC tumors, no functional changes were observed at t = 15 days, but increased perfusion was noticed earlier (t = 9–11 days). Conclusion: The vascular microenvironment response of prostate and lung cancers to radiotherapy consists of both tumor/dose-independent vascular maturation and tumor-dependent functional parameters.